WNTresearch
WNTresearch - WNT researchWNTresearchWNTresearchWNTresearch

WNT research

  • WntResearch
    • About WntResearch
    • Business concept and strategies
    • market Potential
    • Interview with the founder
    • History
    • Scientific advisors
  • Pipeline
    • Foxy-5
      • Phase 1 study
      • Phase 2 study
    • Articles
    • metastases
    • WNT signaling
    • Partners
      • Allucent
      • Biovica
      • SAGA diagnostics
      • The Sage Group
    • Box-5
    • Patents
  • Investor
    • Financial reports
    • Warrants series 2021/2023
    • Share issues
      • Rights issue 2022
    • The Share
    • presentations
    • Financial calendar
  • NEWS
    • Press Releases
    • Subscribe
  • Corporate Governance
    • Nomination committee
    • General meetings
    • Management
    • Board
    • Articles of association
  • Contact
  • English
    • Swedish

Yearly Archives: 2019

WNTresearch   →  Blog Large Image   →  2019
01
Oct
Date October 1, 2019
Categories Uncategorized

Biostock interviews the CEO

...
Read More
Author David
08
Aug
Date August 8, 2019
Categories Uncategorized

WntResearch increases resources for out-licensing Foxy-5

Link...
Read More
Author David
30
Apr
Date April 30, 2019
Categories Uncategorized

Year-end report 2018

Länk...
Read More
Author David
15
Apr
Date April 15, 2019
Categories Uncategorized

Intervju med Ramon Salazar, Coordinating Principal Investigator för fas 2-studien

Link...
Read More
Author David
09
Apr
Date April 9, 2019
Categories Uncategorized

Intervju med professor Ingvar Syk

Link...
Read More
Author David
04
Apr
Date April 4, 2019
Categories Emission

The offer in brief

Link...
Read More
Author David
01
Apr
Date April 1, 2019
Categories Emission

Memorandum new issue

Link...
Read More
Author David
25
Mar
Date March 25, 2019
Categories VD Brev

CEO Letter January 2019

Link...
Read More
Author David

Search

Categories

  • Emission 2
  • Uncategorized 12
  • VD Brev 1

Recent Posts

  • Extraordinary General Meeting on Wednesday, March 10February 5, 2021
  • BioStock publishes interview with acting CEO!October 27, 2020
  • Anders Rabbe is appointed acting CEOOctober 1, 2020
  • BioStock publishes interview with CEO Peter MorsingSeptember 24, 2020
  • BioStock publishes summer interview with CEO Peter MorsingJuly 9, 2020

Archives

  • February 2021
  • October 2020
  • September 2020
  • July 2020
  • April 2020
  • October 2019
  • August 2019
  • April 2019
  • March 2019

A new approach to fight tumour spread!
Foxy-5 is a unique drug candidate:
Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profile

QUICK LINKS

  • Phase 2 study
  • Press Releases
  • shares

Subscribe

    

Copyright © All rights reserved.